Furthermore, FG-3019, a fully human recombinant monoclonal antibody against human CTGF, blocked fibrosis in this model and in two additional clinically relevant rodent fibrosis models, the UUO model of kidney fibrosis and the bleomycin model of lung fibrosis, both of which also respond to TGF-β/Smad-targeted interventions [22-24]. Here, TGFB1 is linked to pulmonary fibrosis.